(Reuters) - CymaBay Therapeutics Inc said its experimental lead drug met the main goal of reducing episodes of gout in a mid-stage study.
The company said the drug, arhalofenate, was shown to be safe and well tolerated.
Gout is a condition affecting joints and muscles when the body acts against a build-up of uric acid in the blood.
(Reporting by Rosmi Shaji in Bengaluru; Editing by Saumyadeb Chakrabarty)
The company said the drug, arhalofenate, was shown to be safe and well tolerated.
Gout is a condition affecting joints and muscles when the body acts against a build-up of uric acid in the blood.
(Reporting by Rosmi Shaji in Bengaluru; Editing by Saumyadeb Chakrabarty)
via Smart Health Shop Forum http://ift.tt/1B8s6Ne
No comments:
Post a Comment